港股異動 | 石藥集團(1093.HK)反彈逾5% 月內獲共成國際增持530萬股
格隆匯12月15日丨石藥集團(1093.HK)放量反彈5.2%,日前曾創逾8個月新低價。現報7.67港元,成交額放大至10.63億港元,總市值918.39億港元。今日大部分醫藥股均上漲,根據聯交所最新權益披露資料顯示,2020年12月10日獲共成國際有限公司增持90萬股,涉資約660.2萬港元,持股比例上升至6.09%。在本月初亦獲共成國際有限公司增持2次,共440萬股,涉資總額為3248.2萬港元。另外,麥格理料內地醫保藥價談判降幅60%至80%,建議談判結束後撈底藥股。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.